lg bristol l.l.c.

418 east 81st apt 2c
new york, new york 10028

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 06, 2013

NYS DOS ID#
4441792

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - LG BRISTOL L.L.C.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Man accused of burning girl with iron over wrinkled clothes
    By Associated Press - Friday Jul 28, 2017

    BRISTOL, Conn. — A Connecticut man has been arrested on charges that he intentionally burned his girlfriend’s 5-year-old daughter with an iron because she may have wrinkled his clothes. The Bristol Press reports that 33-year-old Victor Diaz, of Bristol, was arraigned Thursday on charges including assault and reckless endangerment. Investigators say he burned the girl...

    Source: New York Post: News
  • Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
    By Ben Fidler - Wednesday Aug 16, 2017

    The recent stumbles for cancer immunotherapy—specifically, combinations of treatments meant to help boost its effectiveness—continued late Tuesday with some disappointing news from one of the leaders in the field, Bristol-Myers Squibb. Bristol (NYSE: BMY) said that a Phase 3 trial testing two of its immunotherapies together in newly diagnosed kidney cancer patients, a study called […]

    Source: Xconomy New York
lg bristol llc new york ny